Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become an integrated, publicly traded biopharma.

Arrakis Therapeutics Inc. has begun its first four programs developing RNA-targeting small molecules -- "rSMs" -- including three oncology programs and one cardiovascular project. But the company's broadly applicable science could eventually yield candidates in multiple therapeutic areas, opening up potential partnerships, Chairman and CEO Michael Gilman told BioCentury...